Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GTP-Binding Proteins | 12 | 2015 | 40 | 1.820 |
Why?
|
| Brain | 9 | 2015 | 965 | 1.100 |
Why?
|
| Heroin | 5 | 2015 | 33 | 0.940 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 8 | 2015 | 112 | 0.860 |
Why?
|
| Membrane Transport Proteins | 4 | 2005 | 39 | 0.820 |
Why?
|
| Tropanes | 3 | 2008 | 14 | 0.720 |
Why?
|
| Cocaine | 7 | 2015 | 354 | 0.660 |
Why?
|
| Rats | 22 | 2015 | 1895 | 0.660 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 4 | 2008 | 22 | 0.630 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 13 | 2013 | 35 | 0.600 |
Why?
|
| Receptors, Opioid, mu | 3 | 2013 | 36 | 0.580 |
Why?
|
| Spinal Cord | 4 | 2007 | 137 | 0.540 |
Why?
|
| Isothiocyanates | 2 | 2008 | 14 | 0.540 |
Why?
|
| Receptor, Adenosine A1 | 3 | 2006 | 9 | 0.530 |
Why?
|
| Biogenic Monoamines | 3 | 2008 | 10 | 0.510 |
Why?
|
| Animals | 29 | 2015 | 8199 | 0.490 |
Why?
|
| Receptors, G-Protein-Coupled | 3 | 2007 | 89 | 0.480 |
Why?
|
| Cannabinoids | 3 | 2006 | 56 | 0.480 |
Why?
|
| Carrier Proteins | 3 | 2013 | 145 | 0.450 |
Why?
|
| Corpus Striatum | 3 | 2013 | 69 | 0.450 |
Why?
|
| Membrane Transport Modulators | 2 | 2005 | 7 | 0.440 |
Why?
|
| Narcotics | 4 | 2015 | 32 | 0.420 |
Why?
|
| Behavior, Animal | 3 | 2015 | 299 | 0.420 |
Why?
|
| Protein Binding | 10 | 2015 | 244 | 0.410 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 111 | 0.370 |
Why?
|
| Nerve Tissue Proteins | 2 | 2004 | 124 | 0.370 |
Why?
|
| Spinal Nerves | 5 | 2011 | 68 | 0.360 |
Why?
|
| Rats, Sprague-Dawley | 13 | 2015 | 897 | 0.350 |
Why?
|
| Rats, Inbred F344 | 7 | 2015 | 151 | 0.340 |
Why?
|
| Signal Transduction | 3 | 2005 | 727 | 0.340 |
Why?
|
| Analgesics, Opioid | 2 | 2011 | 252 | 0.330 |
Why?
|
| Amygdala | 1 | 2011 | 60 | 0.320 |
Why?
|
| Hyperalgesia | 1 | 2011 | 83 | 0.320 |
Why?
|
| Conditioning, Operant | 1 | 2011 | 122 | 0.320 |
Why?
|
| Neurons | 2 | 2004 | 486 | 0.300 |
Why?
|
| Drug Tolerance | 3 | 2007 | 40 | 0.280 |
Why?
|
| Nortropanes | 1 | 2008 | 3 | 0.280 |
Why?
|
| Dopamine Uptake Inhibitors | 4 | 2015 | 147 | 0.280 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2007 | 10 | 0.260 |
Why?
|
| Heroin Dependence | 1 | 2007 | 8 | 0.260 |
Why?
|
| Methadone | 1 | 2007 | 12 | 0.260 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 14 | 0.250 |
Why?
|
| Self Administration | 6 | 2015 | 382 | 0.250 |
Why?
|
| Male | 21 | 2015 | 19441 | 0.240 |
Why?
|
| Receptors, Cannabinoid | 4 | 2011 | 33 | 0.240 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 4 | 2011 | 18 | 0.240 |
Why?
|
| Gyrus Cinguli | 2 | 2003 | 26 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 717 | 0.230 |
Why?
|
| Brain Chemistry | 1 | 2005 | 46 | 0.230 |
Why?
|
| Autoradiography | 6 | 2015 | 51 | 0.220 |
Why?
|
| Apomorphine | 1 | 2005 | 10 | 0.220 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2005 | 35 | 0.220 |
Why?
|
| Pain Threshold | 1 | 2005 | 93 | 0.220 |
Why?
|
| Cerebellum | 1 | 2004 | 25 | 0.210 |
Why?
|
| Glutamic Acid | 1 | 2004 | 50 | 0.210 |
Why?
|
| Methylphenidate | 1 | 2004 | 36 | 0.200 |
Why?
|
| Receptors, Drug | 1 | 2002 | 19 | 0.190 |
Why?
|
| Hydrocarbons, Iodinated | 1 | 2002 | 1 | 0.180 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 78 | 0.170 |
Why?
|
| Nucleus Accumbens | 2 | 2014 | 121 | 0.160 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2011 | 13 | 0.140 |
Why?
|
| Arachidonic Acids | 2 | 2011 | 29 | 0.140 |
Why?
|
| Pain | 3 | 2007 | 304 | 0.140 |
Why?
|
| Endocannabinoids | 2 | 2011 | 44 | 0.140 |
Why?
|
| Radioligand Assay | 3 | 2007 | 24 | 0.130 |
Why?
|
| Adenosine | 4 | 2006 | 68 | 0.130 |
Why?
|
| Piperidines | 2 | 2007 | 137 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 276 | 0.110 |
Why?
|
| Receptors, GABA-B | 1 | 2015 | 19 | 0.110 |
Why?
|
| Baclofen | 1 | 2015 | 26 | 0.110 |
Why?
|
| Neostriatum | 1 | 2015 | 28 | 0.110 |
Why?
|
| Binding, Competitive | 2 | 2007 | 43 | 0.110 |
Why?
|
| Prosencephalon | 2 | 2005 | 8 | 0.110 |
Why?
|
| Ibogaine | 1 | 2013 | 3 | 0.100 |
Why?
|
| Guanosine Triphosphate | 2 | 2005 | 11 | 0.100 |
Why?
|
| Thalamus | 1 | 2013 | 36 | 0.100 |
Why?
|
| Dopamine | 2 | 2008 | 262 | 0.100 |
Why?
|
| Receptors, Opioid, delta | 1 | 2013 | 15 | 0.100 |
Why?
|
| Binding Sites | 2 | 2004 | 144 | 0.100 |
Why?
|
| Sulfur Radioisotopes | 2 | 2002 | 8 | 0.090 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2013 | 68 | 0.090 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2013 | 80 | 0.090 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2002 | 11 | 0.090 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Receptor, Muscarinic M4 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Glycerides | 1 | 2011 | 14 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2008 | 58 | 0.080 |
Why?
|
| Naltrexone | 1 | 2011 | 23 | 0.080 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 97 | 0.080 |
Why?
|
| Narcotic Antagonists | 1 | 2011 | 47 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2008 | 99 | 0.080 |
Why?
|
| Random Allocation | 2 | 2015 | 247 | 0.080 |
Why?
|
| Isotopes | 2 | 2011 | 10 | 0.080 |
Why?
|
| HIV Infections | 1 | 2015 | 450 | 0.070 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2008 | 6 | 0.070 |
Why?
|
| Dopamine Antagonists | 2 | 2008 | 31 | 0.070 |
Why?
|
| Iodine Radioisotopes | 2 | 2014 | 22 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2011 | 349 | 0.070 |
Why?
|
| Allosteric Regulation | 2 | 2005 | 13 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2014 | 109 | 0.070 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 95 | 0.070 |
Why?
|
| Ligation | 2 | 2005 | 64 | 0.070 |
Why?
|
| Receptors, Muscarinic | 1 | 2007 | 21 | 0.060 |
Why?
|
| Indans | 1 | 2007 | 31 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 37 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 1083 | 0.060 |
Why?
|
| Sulfur Isotopes | 1 | 2006 | 3 | 0.060 |
Why?
|
| Theophylline | 1 | 2006 | 4 | 0.060 |
Why?
|
| Sensory Thresholds | 1 | 2006 | 28 | 0.060 |
Why?
|
| Physical Stimulation | 1 | 2006 | 83 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2006 | 62 | 0.060 |
Why?
|
| Eating | 1 | 2007 | 77 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2005 | 87 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 332 | 0.060 |
Why?
|
| Rats, Long-Evans | 2 | 2003 | 92 | 0.060 |
Why?
|
| Morphine Derivatives | 1 | 2005 | 3 | 0.060 |
Why?
|
| Membranes | 1 | 2005 | 12 | 0.060 |
Why?
|
| Time Factors | 2 | 2015 | 2205 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 942 | 0.060 |
Why?
|
| Yohimbine | 1 | 2005 | 7 | 0.060 |
Why?
|
| Spiperone | 1 | 2005 | 1 | 0.060 |
Why?
|
| Time | 1 | 2005 | 27 | 0.060 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2005 | 43 | 0.060 |
Why?
|
| Mechanoreceptors | 1 | 2005 | 31 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2005 | 86 | 0.050 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2005 | 51 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2004 | 13 | 0.050 |
Why?
|
| Membrane Potentials | 1 | 2004 | 76 | 0.050 |
Why?
|
| Thiophenes | 1 | 2004 | 24 | 0.050 |
Why?
|
| Kinetics | 1 | 2004 | 250 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 14 | 0.050 |
Why?
|
| Ibotenic Acid | 1 | 2002 | 3 | 0.050 |
Why?
|
| Tritium | 1 | 2002 | 19 | 0.050 |
Why?
|
| Benzoxazines | 1 | 2002 | 28 | 0.050 |
Why?
|
| Morpholines | 1 | 2002 | 47 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2002 | 53 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2004 | 839 | 0.050 |
Why?
|
| Guanosine Diphosphate | 1 | 2002 | 4 | 0.050 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 2002 | 6 | 0.050 |
Why?
|
| Serotonin | 1 | 2002 | 44 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 232 | 0.040 |
Why?
|
| Analgesics | 1 | 2002 | 111 | 0.040 |
Why?
|
| Humans | 5 | 2013 | 32282 | 0.030 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2007 | 200 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2015 | 47 | 0.030 |
Why?
|
| Tyrosine | 1 | 2015 | 24 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 250 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 101 | 0.030 |
Why?
|
| Cricetulus | 1 | 2013 | 21 | 0.030 |
Why?
|
| CHO Cells | 1 | 2013 | 29 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2013 | 80 | 0.020 |
Why?
|
| Xanthines | 2 | 2004 | 10 | 0.020 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2013 | 76 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 79 | 0.020 |
Why?
|
| Female | 2 | 2013 | 19945 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 346 | 0.020 |
Why?
|
| Pirenzepine | 1 | 2011 | 3 | 0.020 |
Why?
|
| Parasympatholytics | 1 | 2011 | 5 | 0.020 |
Why?
|
| Food Deprivation | 1 | 2011 | 4 | 0.020 |
Why?
|
| Maze Learning | 1 | 2011 | 15 | 0.020 |
Why?
|
| Reversal Learning | 1 | 2011 | 5 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 90 | 0.020 |
Why?
|
| Attention | 1 | 2011 | 84 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 478 | 0.020 |
Why?
|
| Hippocampus | 1 | 2011 | 216 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 26 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 9 | 0.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2008 | 12 | 0.020 |
Why?
|
| Amines | 1 | 2008 | 23 | 0.020 |
Why?
|
| Drug Design | 1 | 2008 | 51 | 0.020 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2008 | 41 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 125 | 0.020 |
Why?
|
| Mice | 1 | 2013 | 2571 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 408 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 26 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 536 | 0.010 |
Why?
|
| Cannabis | 1 | 2004 | 30 | 0.010 |
Why?
|
| Research | 1 | 2004 | 81 | 0.010 |
Why?
|
| Microdialysis | 1 | 2002 | 41 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2002 | 119 | 0.010 |
Why?
|